Healthcare Triangle, Inc.
3.0100+0.13 (+4.51%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · HCTI · USD
Key Stats
Market Cap
17.68MP/E (TTM)
-Basic EPS (TTM)
-112.08Dividend Yield
0%Recent Filings
8-K
Warrant inducement boosts cash
Healthcare Triangle induced holders to exercise existing warrants for 1,429,528 shares at a slashed $2.00 per share, netting $2.85 million in gross proceeds on October 2, 3, and 8, 2025. In exchange, it issued new unregistered warrants for the same number of shares at $3.00 each, exercisable post-stockholder approval for five years. Funds will bolster working capital. New warrants hinge on approval.
8-K
Nasdaq Compliance Restored
Healthcare Triangle resolved its Nasdaq compliance issue on September 15, 2025, by amending the acquisition agreement for Niyama Healthcare and Ezovion Solutions to require shareholder approval before issuing shares representing 33.8% of pre-transaction stock. This clears the path for the deal, bolstering the company's push into EHR, cloud, and AI markets. Backlog stands at $15.8M committed, targeting ~$20M revenue for 2025 with high-margin growth engines. Forward-looking projections carry execution risks.
10-Q
Q2 FY2025 results
Healthcare Triangle posted Q2 revenue of $3.6M, up 19% year-over-year yet flat quarter-over-quarter (derived), fueled by software services surging 217% to $2.1M while managed services dipped 38% to $1.4M; gross margins shrank to 14% from 30% amid lower-margin acquired contracts, driving operating losses to $1.4M, up slightly from last year, with net losses at $1.4M versus $1.5M prior. The $3.1M YTD net loss aligns with diluted EPS of -$2.56 across 1.2M weighted shares, no anti-dilution flagged. A June acquisition of Niyama Healthcare assets closed for $5.7M (cash/stock/contingent), adding $5.7M goodwill and boosting international reach in mental health tech across India, Southeast Asia, and Europe. Cash climbed to $3.2M with $12.0M financing inflows offsetting $8.2M operating outflows; short-term debt fell to $0.4M under an 8.5% facility. Free cash flow not disclosed in the 10-Q. Yet customer concentration lingers, with top five accounting for 58% of sales.
8-K
Reverse split for Nasdaq compliance
Healthcare Triangle executed a 1-for-249 reverse stock split on August 1, 2025, slashing outstanding shares from 1,452,124,283 to 5,831,816 to meet Nasdaq's $1.00 minimum bid price rule. This move, approved by shareholders in February, preserves ownership percentages while adjusting warrants and options proportionally—no fractions issued, just round-ups. Trading resumes split-adjusted under HCTI. Yet Nasdaq delisting looms if compliance fails.
8-K
Nasdaq grants HCTI listing extension
Healthcare Triangle dodged delisting on July 2, 2025, when Nasdaq's Panel granted continued listing on the Capital Market, deeming the company compliant with shareholders' equity rules while excusing prior public interest issues. The firm must execute a reverse stock split by August 8 and sustain a $1 bid price for 20 consecutive days by September 5, under a one-year panel monitor. This buys time to stabilize trading. Yet risks linger if compliance falters.
IPO
Employees
Sector
Industry
BEAT
Heartbeam, Inc.
1.60+0.01
CCLD
CareCloud, Inc.
3.02-0.02
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.39+0.00
DH
Definitive Healthcare Corp.
2.77-0.17
ESSI
Eco Science Solutions, Inc.
0.02-0.00
FORA
Forian Inc.
2.33-0.02
HCAT
Health Catalyst, Inc
3.34-0.04
HNGE
Hinge Health, Inc.
49.60-1.37
SOPH
SOPHiA GENETICS SA
4.54+0.45
VEEV
Veeva Systems Inc.
286.67-4.68